Palisade Bio Participates in Virtual Investor “What this Means” Segment
Palisade Bio (Nasdaq: PALI) has released a Virtual Investor 'What This Means' segment featuring Chief Medical Officer Mitchell Jones, MD, PhD. The segment focuses on the company's recent microbiome study that confirmed bacterial enzymes for local bioactivation of their lead product candidate, PALI-2108. This development is significant for Palisade Bio's planned Phase 1 human clinical study for the treatment of Ulcerative Colitis.
The company, which specializes in developing therapeutics for autoimmune, inflammatory, and fibrotic diseases, views this as an important step forward in their research. The Virtual Investor segment is now available online, providing investors and interested parties with insights into the implications of this study for Palisade Bio's future clinical trials and potential treatment options.
Palisade Bio (Nasdaq: PALI) ha rilasciato un segmento Virtual Investor 'Cosa significa questo' con il Chief Medical Officer Mitchell Jones, MD, PhD. Il segmento si concentra sul recenti studio del microbioma dell'azienda, che ha confermato l'azione di enzimi batterici per la bioattivazione locale del loro principale candidato prodotto, PALI-2108. Questo sviluppo è significativo per il piano di studio clinico di fase 1 su esseri umani dell’azienda per il trattamento della colite ulcerosa.
L'azienda, specializzata nello sviluppo di trattamenti per malattie autoimmuni, infiammatorie e fibrotiche, considera questo un passo importante nella propria ricerca. Il segmento Virtual Investor è ora disponibile online, fornendo a investitori e parti interessate approfondimenti sulle implicazioni di questo studio per i futuri trial clinici di Palisade Bio e le potenziali opzioni di trattamento.
Palisade Bio (Nasdaq: PALI) ha lanzado un segmento de Inversionista Virtual 'Qué significa esto' con el Director Médico Mitchell Jones, MD, PhD. El segmento se centra en el reciente estudio del microbioma de la empresa, que confirmó las enzimas bacterianas para la bioactivación local de su candidato principal de producto, PALI-2108. Este desarrollo es significativo para el estudio clínico humano de fase 1 planificado por Palisade Bio para el tratamiento de colitis ulcerosa.
La empresa, especializada en el desarrollo de terapias para enfermedades autoinmunes, inflamatorias y fibróticas, considera esto un paso importante en su investigación. El segmento de Inversionista Virtual ya está disponible en línea, proporcionando a inversores y partes interesadas información sobre las implicaciones de este estudio para los futuros ensayos clínicos de Palisade Bio y las posibles opciones de tratamiento.
팔리세이드 바이오(Nasdaq: PALI)가 최고 의료 책임자 미첼 존스(Mitchell Jones, MD, PhD)와 함께하는 가상 투자자 '이것이 의미하는 바' 세그먼트를 발표했습니다. 이 세그먼트는 최근 미생물군계 연구에 초점을 맞추고 있으며, 이는 그들의 주요 제품 후보, PALI-2108의 국소 생체 활성화를 위한 박테리아 효소를 확인했습니다. 이 개발은 팔리세이드 바이오의 1상 인간 임상 연구 계획에 있어 중요한 의미가 있습니다, 궤양성 대장염 치료를 목표로 하고 있습니다.
자체 면역질환, 염증성 질환 및 섬유증 치료제를 개발하는 데 특화된 이 회사는 이를 연구에서 중요한 진전으로 보고 있습니다. 가상 투자자 세그먼트는 온라인에서 이용 가능하며, 투자자와 이해 관계자들에게 이 연구가 팔리세이드 바이오의 향후 임상 시험 및 잠재적 치료 옵션에 미치는 시사점에 대한 통찰력을 제공합니다.
Palisade Bio (Nasdaq: PALI) a publié un segment Investisseur Virtuel 'Que cela signifie-t-il?' avec le directeur médical Mitchell Jones, MD, PhD. Le segment se concentre sur la dernière étude du microbiome de l'entreprise, qui a confirmé les enzymes bactériennes pour la bioactivation locale de son candidat principal, PALI-2108. Ce développement est significatif pour le prévu essai clinique humain de phase 1 pour le traitement de la colite ulcéreuse.
L'entreprise, qui se spécialise dans le développement de thérapies pour les maladies auto-immunes, inflammatoires et fibrosantes, considère cela comme une étape importante dans sa recherche. Le segment Investisseur Virtuel est maintenant disponible en ligne, fournissant aux investisseurs et aux parties intéressées des informations sur les implications de cette étude pour les futurs essais cliniques de Palisade Bio et les options de traitement potentielles.
Palisade Bio (Nasdaq: PALI) hat ein Segment für virtuelle Investoren mit dem Chief Medical Officer Mitchell Jones, MD, PhD, veröffentlicht, das 'Was bedeutet das?' heißt. Das Segment konzentriert sich auf die neuste Mikrobiomstudie des Unternehmens, die bakterielle Enzyme zur lokalen Bioaktivierung ihres führenden Produktkandidaten, PALI-2108, bestätigt hat. Diese Entwicklung ist bedeutend für die geplante Phase-1-Studie am Menschen zur Behandlung von ulzerativer Kolitis.
Das Unternehmen, das auf die Entwicklung von Therapeutika für autoimmune, entzündliche und fibrotische Erkrankungen spezialisiert ist, betrachtet dies als einen wichtigen Fortschritt in seiner Forschung. Das Segment für virtuelle Investoren ist jetzt online verfügbar und gibt Investoren sowie Interessierten Einblicke in die Bedeutung dieser Studie für die zukünftigen klinischen Studien von Palisade Bio und mögliche Behandlungsoptionen.
- Successful completion of microbiome study confirming local bioactivation of lead product PALI-2108
- Progress towards planned Phase 1 human clinical study for Ulcerative Colitis treatment
- None.
Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108
Carlsbad, CA, July 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a Virtual Investor “What This Means” segment.
As part of this “What this Means” segment, Mitchell Jones, MD, PhD, Chief Medical Officer of Palisade Bio discusses the successful completion of a microbiome study confirming bacterial enzymes for local bioactivation of lead product candidate, PALI-2108, and what this means for its planned Phase 1 human clinical study for the treatment of Ulcerative Colitis.
The Virtual Investor “What This Means” segment featuring Palisade Bio is now available here. Additional videos from the “What This Means” series are available on demand at www.virtualinvestorco.com.
About Palisade Bio
Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
PALI@jtcir.com
FAQ
What is the significance of Palisade Bio's recent microbiome study for PALI-2108?
What is PALI-2108 being developed to treat?
When did Palisade Bio (PALI) release the Virtual Investor 'What This Means' segment?
Who presented Palisade Bio's (PALI) findings in the Virtual Investor segment?
